Sustainability at Kindeva

pMDIs are responsible for 3% of global emissions in the U.K.* At Kindeva, we’re on a mission to change that. Our passion for innovation is matched by a track record of leadership in sustainability.

Additional Resources:

Six Inhaler Sustainability Myths – And Why They Must Be Busted

by Louise Righton, Global Strategic Marketing Leader, Inhaled Drug Delivery

A study authored by Frontier Economics and provided during the PCRS Respiratory Conference 2021. For additional details, click here. 

*NHS England and NHS Improvement, Delivering a ‘Net Zero’ National Health Service (London: Skipton House, 2020)

• Kindeva has installed pilot scale lines and is installing two new manufacturing lines capable of filling inhalers with HFA-152a and/or HFO-1234ze propellants that have 90% and 99.9% lower Global Warming Potential (GWP) than P134a, the greenest propellant currently used. Click here to read more on initial efforts.
• By 2025, we will strive to introduce the first products using these propellants to the market, subject to regulatory approvals.
  • 1st commercial green propellant line
    • Registration batches: 2024
    • Full commercial scale: 2025

We will lead the industry’s transition to greener gasses just as we led the transition from CFC- to HFA-based inhalers in the 1990s, developing the world’s first CFC-free pMDI and the world’s first CFC-free nasal pMDI.

Guided by this extensive history of innovation, we remain active in the continuing exploration and creation of more environmentally friendly products and processes that meet evolving regulations. The adaptability of our components and hardware coupled with our team of industry leaders provides the right skills to match the performance of new, greener devices to that of current ones.

Read our blog for thoughts on responsibly transitioning to green propellants and recommendations for navigating changing guidance successfully.